Novo Nordisk AS (XBUL:NOV) Net Income (Continuing Operations) : лв26,289 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Novo Nordisk AS Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Novo Nordisk AS's Net Income (Continuing Operations) for the three months ended in Mar. 2025 was лв7,313 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was лв26,289 Mil.

Novo Nordisk AS Net Income (Continuing Operations) Historical Data

The historical data trend for Novo Nordisk AS's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Net Income (Continuing Operations) Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

11,974.22

12,610.82

13,739.48

21,276.96

24,641.08

Novo Nordisk AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income (Continuing Operations)	Get a 7-Day Free Trial															6,436.36	5,025.20	7,062.14	6,888.12	7,313.07

Novo Nordisk AS Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was лв26,289 Mil.

Novo Nordisk AS (XBUL:NOV) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Novo Nordisk AS Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (XBUL:NOV) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.